Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease [Yahoo! Finance]
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $55.00 to $57.00. They now have an "outperform" rating on the stock.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $53.00 to $75.00. They now have a "sector outperform" rating on the stock.